Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
永泰生物-B:2023年度報告
Immunotech Biopharm Posts Nearly 335 Million Yuan Loss in 2023
Immunotech Biopharm (HKG:6978) reported a loss and total comprehensive expense attributable to owners of approximately 334.8 million yuan for the year ended Dec. 31, 2023, compared with a loss of 318.
Yongtai Bio-B (06978.HK)'s annual loss increased to 335 million yuan
Gelonghui, March 28, 丨 Yongtai Bio-B (06978.HK) announced that for the year ended December 31, 2023, the company's other revenue increased by about RMB 1.4 million or about 15.4% from about RMB 9.1 million in the previous year to about RMB 10.5 million. R&D expenditure increased by approximately RMB 1.1 million, or approximately 0.6%, from approximately RMB 176.2 million in the previous year to approximately RMB 177.3 million in the same year. Total loss and overall expenses during the year increased by approximately RMB321.1 million for the year ended 31 December 2022 by approximately RMB14
Yongtai Bio-B (06978) Announces 2023 Annual Results with R&D Expenses of 177 Million Yuan to Accelerate Research on Expanded Indications for EAL
Yongtai Bio-B (06978) disclosed the 2023 annual results announcement. The company achieved about 1 other revenue during the reporting period...
IMMUNOTECH-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Yongtai Bio-B (06978.HK) plans to hold a board meeting on March 28 to approve the annual results
Gelonghui March 18 | Yongtai Bio-B (06978.HK) announced that the company plans to hold a board meeting on March 28, 2024 (Thursday) to consider and approve (including) the annual results of the company and its subsidiaries for the year ended 31 December 2023 and their announcements.
IMMUNOTECH-B: DATE OF BOARD MEETING
Changes in Hong Kong stocks | Yongtai Bio-B (06978) rose more than 8%. The company recently joined hands with Corning to expand product commercialization cooperation
The Zhitong Finance App learned that Yongtai Bio-B (06978) rose more than 8%. As of press release, it had risen 8.41% to HK$3.61. According to news, Yongtai Biotech and Corning signed a memorandum of business cooperation in Beijing on March 1. According to reports, with the signing of the Memorandum of Business Cooperation, the two sides will carry out deeper cooperation in the development and marketing of customized products, testing laboratories, new products, etc., to promote the commercialization and implementation of Yongtai's important R&D pipelines. A previous research report by Societe Generale Securities pointed out that cellular immunotherapy has grown rapidly in recent years and has shown great potential. The company is deeply involved in cellular immunotherapy
A major favorable raid, and the 1.6 trillion innovative drug sector is booming!
The advantage suddenly “smashed” into the pharmaceutical sector!
Yongtai Bio-B (06978) joins hands with Corning to expand product commercialization cooperation
This time, a memorandum of business cooperation was signed to prepare the two sides to expand commercialization of Yongtai products.
A quick overview of the Hong Kong market | The Hang Seng Index rose nearly 2%, and the Science Index rose nearly 3%; insurance, real estate and other sectors were strong throughout the day
Technet stocks were strong. Meituan rose nearly 5%, Bilibili and Kuaishou rose more than 3%, Xiaomi and Jingdong rose more than 2%, Baidu, Ali, and Tencent rose more than 1%, and NetEase followed; insurance stocks were strong throughout the day. China Ping An rose more than 6%, China Life Insurance rose nearly 5%, and AIA Insurance rose more than 2%.
Selected announcements | Air China's passenger turnover increased by nearly 70% year-on-year in January; Xinhua Insurance's premium income fell by more than 15% in January
China Eastern Airlines shares: passenger turnover increased 87.97% year on year in January; China Southern Airlines shares: passenger turnover increased 56.47% year on year in January; Kuaishou-W: spent HK$39.97 million to buy back 912,000 shares on February 19.
Immunotech Biopharm Obtains Clinical Trial Nod in China for Leukemia Drug
Immunotech Biopharm (HKG:6978) said the Centre for Drug Evaluation of China's National Medical Products Administration has granted clinical trial approval for the firm's aT19 injection. Phase I clinic
Yongtai Bio-B (06978.HK): Drug Evaluation Center Approves AT19 Injection New Drug Phase I Clinical Trial (IND) Application
Gelonghui, Feb. 19 | Yongtai Bio-B (06978.HK) announced that the company has received approval from the Drug Evaluation Center (Drug Evaluation Center) of the China Drug Administration (Drug Evaluation Center) for the Phase 1 Clinical Trial (IND) application for aT19 injection. AT19 injection is an injection targeting CD19 chimeric antigen receptor T cells (CAR-T cells) used sequentially to prevent CD19 positive recurrence in patients under 25 with recurrent refractory B-cell-derived acute lymphocytic leukemia (B-ALL). The goal of this injection is to address CD19-targeting CAR-T cells against B
Intraday Overview | The three major indices rose slightly, and the Tech Index rose nearly 2%; auto stocks and biotech stocks rose strongly. NIO rose nearly 8%, and Pharmaceutical Biotech rose more than 9%
Most Technology Network stocks rose, with Station B up more than 4%; Meituan and NetEase up more than 3%; mobile phone equipment stocks showed active performance, with Shunyu Optical Technology up more than 7% and Gaowei Electronics by more than 5%; pharmaceutical distribution stocks improved, Ali Health rose more than 8%, and JD Health rose nearly 5%.
Intraday Overview | The Tech Index fell more than 2%, Apple concept stocks and pharmaceutical stocks had the highest declines, and Shunyu Optical Technology fell more than 8%
Technet stocks collectively weakened, with Xiaomi falling nearly 4%, Meituan falling nearly 3%, and Kuaishou falling more than 2%; domestic housing stocks continued to decline, with Country Garden falling more than 3%; Longhu Group, Xincheng Development, and Sunac China falling nearly 2%; auto stocks were weak, with Zero Sports Auto and NIO falling more than 5%, and Xiaopeng Motors falling more than 4%.
Yongtai Bio-B (06978) was successfully selected for the 2023 “one-stop” application demonstration direction and promotion agency list of key products and processes
Yongtai Biotech was successfully selected as the recommended agency for the key application demonstration direction of “activated autolymphocyte products”.
Announcement selection: Great Wall Motor's sales last month increased by more than 40% year on year; China Railway Construction recently won a bid of 73.298 billion yuan for a major project
C&D International Group: The cumulative contract sales amount in 2023 was about 137.96 billion yuan, an increase of 13.5% over the previous year; Kingsley Biotech: Legend Biotech and Novartis completed a global licensing agreement.
No Data